HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPY
- 1 December 1998
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 160, 2021-2024
- https://doi.org/10.1097/00005392-199812010-00022
Abstract
We define the incidence of thromboembolic events in patients receiving multiagent chemotherapy for urothelial cancer. A retrospective chart review of 271 consecutive patients who received multi-agent cisplatin based chemotherapy for transitional cell carcinoma at Princess Margaret Hospital between 1986 and 1996 was performed. Indications for chemotherapy included adjuvant treatment following resection of high risk disease (13%), and primary management of locally advanced and metastatic disease (87%). Vascular events occurred in 35 patients (12.9%) receiving chemotherapy, including 18 deep vein thromboses, 9 pulmonary emboli, 7 arterial thromboses, 3 cerebrovascular events, 1 superficial phlebitis and 1 angina pectoris (4 patients had deep vein thrombosis and pulmonary embolus). Three events were directly fatal. Overall, 3.6% of chemotherapy cycles were complicated by vascular events with 27 events (77%) occurring during the first 2 cycles. Risk factors for vascular events included a large pelvic mass and concomitant peripheral vascular or coronary artery disease. Substantial morbidity was associated with vascular events and median hospital stay of 10 days. There is a substantial risk of venous and arterial vascular events in patients receiving cisplatin based chemotherapy for urothelial transitional cell carcinoma. Prophylactic anticoagulation should be considered in patients with risk factors for thromboembolic disease.Keywords
This publication has 12 references indexed in Scilit:
- A Randomized Trial of Radical Cystectomy Versus Radical Cystectomy Plus Cisplatin, Vinblastine and Methotrexate Chemotherapy for Muscle Invasive Bladder CancerJournal of Urology, 1996
- Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.Journal of Clinical Oncology, 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Cisplatin‐induced platelet activation requires mononuclear cells: role of GMP‐140 and modulation of procoagulant activityBritish Journal of Haematology, 1993
- Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.Journal of Clinical Oncology, 1991
- Perioperative Methotrexate, Vinblastine, Doxorubicin and Cisplatin (M-VAC) for Poor Risk Transitional Cell Carcinoma of the Bladder: An Eastern Cooperative Oncology Group Pilot StudyJournal of Urology, 1990
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Chemotherapy for Transitional Cell Carcinoma: The Princess Margaret Hospital ExperienceJournal of Urology, 1989
- The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patientsCancer, 1989
- Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.Journal of Clinical Oncology, 1987
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985